Market Overview

UPDATE: Soaring 19%, Deutsche Bank Initiates Coverage on Arrowhead Research

Share:
Related ARWR
Mid-Day Market Update: Breitburn Energy Partners Drops Following News of Distribution Suspension; Mattress Firm Shares Surge
Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA
Arrowhead Research net loss improves in FQ1 (Seeking Alpha)

Rating reports today from Deutsche Bank includes analyst Alethia Young initiating coverage on Arrowhead Research (NASDAQ: ARWR). The initial rating is a Buy with a price target of $45.

Young notes, "Arrowhead is an early stage platform company that we believe could have the market cap potential of $4-5B as it becomes de-risked. The company's lead target is ARC-520 for Hepatitis B (HBV). Our HBV deep dive suggests ARC-520 could grow the market from $2B to $5B and see $5.2B peak sales WW."

Some risks that were mentioned includes possible safety and efficacy issues relating to drug and platform technology. Possible clinical delays on ARC-520 may also hinder then ability of ARWR to reach its potential.

ARWR closed previous trading session at $21.14 and is currently trading around the $25.23 mark, up over 19%. The price target of $45 displays a 170% upside from current trading prices.

Latest Ratings for ARWR

DateFirmActionFromTo
Sep 2015Piper JaffrayMaintainsOverweight
Apr 2015JefferiesDowngradesBuyHold
Jan 2015Deutsche BankDowngradesBuyHold

View More Analyst Ratings for ARWR
View the Latest Analyst Ratings

Posted-In: Deutsche BankNews Price Target Initiation Markets Analyst Ratings

 

Related Articles (ARWR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters